BaiXiaoAi AI Companion for Cancer Patient Follow-up

Application of BaiXiaoAi Companion AI in the Diagnosis, Treatment, and Follow-up Management of Oncology Patients: A Single-Center, Prospective, Exploratory Study

This is a prospective, single-center, exploratory study designed to evaluate the accuracy, user engagement, and user experience of the BaiXiaoAi Companion AI. Upon signing the informed consent form and enrollment, a dedicated "Doctor-Nurse-Patient-AI" WeChat group will be established for each participant. Within the group, the BaiXiaoAi AI will provide timely responses based on patient communications and proactively push information regarding disease management and patient education.

This is a prospective, single-center, exploratory clinical study aiming to comprehensively assess the diagnostic accuracy, user engagement efficacy, and subjective user experience of the BaiXiaoAi Companion AI system in the context of clinical patient management.

Following the voluntary signing of the informed consent document and formal enrollment into the study cohort, each participant will be assigned to a dedicated WeChat group adopting a "Doctor-Nurse-Patient-AI" quadruple collaborative model. Within this closed communication platform, the BaiXiaoAi Companion AI is programmed to perform two core functions: first, it delivers real-time, contextually tailored responses to patients' inquiries, symptom descriptions, and daily health-related communications shared within the group; second, it proactively disseminates personalized, evidence-based content covering disease-specific management protocols, medication adherence guidance, lifestyle modification recommendations, and targeted patient education materials. These interventions are designed to facilitate seamless interaction between medical providers and patients while leveraging AI-driven tools to augment the continuity of care outside of traditional clinical settings.

Inclusion Criteria:

• Adults aged 18 years or older;
• Patients with a confirmed diagnosis of malignant neoplasms who are currently undergoing treatment or in follow-up, or their primary caregivers;
• Able to read and communicate in Chinese and independently use WeChat;
• Willing and able to provide informed consent.

Exclusion Criteria:

• Presence of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) or cognitive impairment (MMSE score < 24);
• Inability to use WeChat or communicate in Chinese;
• Considered by the investigators to be unsuitable for participation due to psychological or physical conditions.